MTOR and cancer: In order to overcome the inferior pharmacokinetic properties of rapamycin and to further explore the therapeutic utility of mTOR inhibition to combat cancer, numerous analogs of rapamycin were subsequently developed based on the structure of rapamycin as a molecular scaffold.